NewsResearch
TAILORx: What the Breast Cancer Trial Found
TAILORx tested chemotherapy guided by 21-gene recurrence score in breast cancer, measuring invasive disease-free survival. Plain-language summary of a result widely described as practice-influencing — and what it doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A trial designed to take treatment away
Most cancer trials ask whether adding something helps. TAILORx asked the opposite question: who can safely be given less.
The setting was the most common situation in breast cancer. Hormone receptor-positive, HER2-negative, with no cancer in the underarm lymph nodes.
For those women, a test called the 21-gene recurrence score already existed. A high score predicted that chemotherapy would help. A low score predicted a low risk of recurrence without it.
The problem was the middle. Most women land in the midrange, and nobody knew what that score meant for chemotherapy.
The design
TAILORx enrolled 10,273 women. Of the 9,719 who were eligible and had follow-up, 6,711 had a midrange recurrence score of 11 to 25. That is 69 percent of them, which tells you how big the uncertainty was.
Those 6,711 were randomly assigned to chemotherapy plus hormone therapy, or hormone therapy alone.
The design was noninferiority. It was not built to show that hormone therapy alone is better. It was built to show that it is not meaningfully worse.
The endpoint was invasive disease-free survival, defined as freedom from invasive recurrence, a second primary cancer, or death from any cause. Our page on trial endpoints explains what a composite measure like that captures.
What it found
Hormone therapy alone was noninferior. The hazard ratio for invasive recurrence, second cancer or death was 1.08, with a 95 percent confidence interval of 0.94 to 1.24 and a p of 0.26.
At nine years, the two groups looked almost identical.
- Free of invasive disease: 83.3 percent on hormone therapy alone, 84.3 percent with chemotherapy added.
- No recurrence at a distant site: 94.5 percent and 95.0 percent.
- No recurrence at a distant or local site: 92.2 percent and 92.9 percent.
- Alive: 93.9 percent and 93.8 percent.
There was one exception, and it matters. The benefit of chemotherapy varied with the combination of recurrence score and age, with a p of 0.004 for that interaction. Some benefit did show up in women aged 50 or younger with a score of 16 to 25.
Why this was a big result
It let roughly 70 percent of women with the most common form of early breast cancer avoid chemotherapy without giving anything up in outcome.
Avoiding chemotherapy is not a small saving. It means avoiding hair loss, nausea, months of fatigue, infection risk from low white cell counts, nerve damage in the hands and feet, early menopause and infertility, and a small long-term risk of heart damage and of second cancers.
The trial also changed what a pathology report is for. A genomic test on the tumor stopped being an optional extra and became part of the treatment decision. Our page on genetic testing versus genomic testing explains the difference between testing the tumor and testing inherited genes.
What did not change is that everyone in the trial received hormone therapy. Nobody skipped treatment. Our page on adjuvant endocrine therapy covers what those years involve.
When to get checked
TAILORx concerns people already diagnosed. The step before that is finding the cancer.
NCI notes that early breast cancer often has no symptoms, which is why screening exists. The U.S. Preventive Services Task Force recommends a mammogram every two years for women aged 40 to 74.
The changes NCI says to bring to a doctor, whatever your screening schedule:
- A lump in or near the breast, or under the arm.
- A thick or firm area in either place.
- A change in the size or shape of a breast.
- Fluid or discharge from the nipple that is not breast milk.
- A nipple that changes shape, flattens, or points differently.
- Scaly or swollen skin, redness or darkening, or itching on the breast, nipple or areola.
The group picture
SEER figures describe the whole United States population, not the trial group.
Five-year relative survival for female breast cancer is 91.9 percent for cases from 2016 to 2022. By stage it is 100.0 percent while confined to the breast, 87.5 percent once it has reached nearby lymph nodes, and 33.8 percent once it has spread further.
Sixty-four percent are found at that first stage. The American Cancer Society projects 321,910 new cases and 42,140 deaths for 2026, a count SEER reproduces, and SEER's own data give a median age at diagnosis of 64.
What this does not mean
It applies to one specific situation: hormone receptor-positive, HER2-negative, node-negative breast cancer with a midrange recurrence score of 11 to 25. Change any one of those and the answer changes with it. Node-positive disease was not studied here.
Noninferiority is a weaker claim than equivalence. It shows hormone therapy alone is not meaningfully worse. A small true difference cannot be ruled out entirely.
The finding about women aged 50 or younger with a score of 16 to 25 came from a subgroup analysis. Those are exploratory by nature and less certain than the main result, which is exactly why it is stated as a question for a conversation rather than a rule.
And the recurrence score is one input. Tumor size, grade, age and a person's own view of the tradeoff all sit alongside it.
Sources
- Sparano JA et al., Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, N Engl J Med 2018 — NCBI PubMed record via E-utilities — https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=29860917&rettype=abstract&retmode=text
- ClinicalTrials.gov API v2, NCT00310180 — https://clinicaltrials.gov/api/v2/studies/NCT00310180
- NCI, Breast Cancer Signs and Symptoms — https://www.cancer.gov/types/breast/symptoms
- SEER Cancer Stat Facts, Female Breast Cancer — https://seer.cancer.gov/statfacts/html/breast.html
- USPSTF, Breast Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Breast cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.